Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;1(2):391-393.
doi: 10.3892/etm_00000061. Epub 2010 Mar 1.

Role of immunohistochemistry and apoptosis as investigative tools in assessing the prognosis of patients with prostate tumours

Srikumar Chakravarthi  1 , P M Thani, David Low Wee Yang, Linda Tjoa Husin, Nagaraja Lee
Affiliations

Role of immunohistochemistry and apoptosis as investigative tools in assessing the prognosis of patients with prostate tumours

Srikumar Chakravarthi et al. Exp Ther Med. 2010 Mar.

Abstract

Apoptosis is a form of programmed cell death necessary for the regulation of the size of organs in adult life. Disruption of apoptotic pathways has been suggested as an important regulatory mechanism in prostatic tumours. The aim of this study was to examine the expression of apoptosis-regulating genes bcl-2 and p53 using immunohistochemistry, and the Gleason score in core needle biopsy specimens of prostate adenocarcinoma. We studied bcl-2 and p53 expression in 30 cases of low-, 30 cases of intermediate- and 20 cases of high-grade prostate adenocarcinoma. Overexpression of bcl-2 and p53 were noted in 54 and 61 of 80 patients (67.5 and 76.25%), respectively. The statistical analysis of the present data suggested that there is significant relation between p53 and bcl-2 expression, and Gleason score in prostate cancer. Thus, immunohistochemistry is a useful investigative parameter in assessing apoptosis to analyse the prognosis of prostatic tumours.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Photomicrograph showing a large tumour gland exhibiting cytoplasmic positivity for bcl-2 (immunohistochemistry, ×400).
Figure 2.
Figure 2.
Photomicrograph showing a large cluster of tumour cells showing nuclear positivity for p53 (immunohistochemistry, ×400).
See this image and copyright information in PMC

References

    1. Miller DC, Hafez KS, Stewart A. Prostate carcinoma presentation, diagnosis and staging: an update from the National Cancer Data Base. Cancer. 2003;98:1169–1172. - PubMed
    1. Von Eschenbach AC. The biologic dilemma of early carcinoma of prostate. Cancer. 1996;78:326–329. - PubMed
    1. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Arch Pathol Lab Med. 1995;119:1122–1126. - PubMed
    1. Hockenbery D, Nunez C, Milliam C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334–338. - PubMed
    1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–325. - PubMed